Skip to main content

Table 1 Observed parasitaemia in Pk4 vaccinated, CSP/SSP2 vaccinated and control (mock vaccine) groups.

From: Malaria infection by sporozoite challenge induces high functional antibody titres against blood stage antigens after a DNA prime, poxvirus boost vaccination strategy in Rhesus macaques

Experiment # Vaccine group Rhesus ID day1stparasitaemia Mean 1stday parasitaemia day >1.5% parasitaemia Mean day >1.5% parasitaemia
1 Mock* 20H 7 7.0 12 11.5
1 Mock 205 7   12  
1 Mock AB07† 7   11  
1 Mock AB58 7   12  
1 Mock Q121 7   11  
2 csp/ssp2 IIG 9 8.2 11 11.2
2 csp/ssp2 AB67 8   11  
2 csp/ssp2 AC70 8   12  
2 csp/ssp2 Q134 8   10  
2 csp/ssp2 AK52 8   12  
2 csp/ssp2 IIG 9   11  
2 Pk4** 281 11 9.5 14 13
2 Pk4 284 9   13  
2 Pk4 3000 9   13  
2 Pk4 3129 9   13  
2 Pk4 19159 9   13  
2 Pk4 262 9 9.5 Never Never
2 Pk4 299 10   Never  
2 Pk4 3086 11   Never  
2 Pk4 3098 9   Never  
2 Pk4 AB34 9   Never  
1 Pk4 Q120 9   Never  
1 Pk4 T152 10   Never  
3 Pk4 228 10   Never  
  1. † Animal died before the end of the study. No post challenge sample was available.
  2. * Mock, vaccine comprised of empty DNA vector and empty COPAK vaccinia virus
  3. ** Pk4, vaccine comprised of four Plasmodium knowlesi antigens, csp/ssp2/ama1/msp142
  4. Day to 1st parasitaemia is the day of patency of parasites on thin smear. Day >1.5% parasitaemia is the day of drug treatment. All vaccinated animals were primed with 3 DNA vaccine injections and boosted with recombinant poxviruses encoding the Pk4 antigens. Control (mock) animals received mock DNA vaccine and empty poxvirus. Subjects were taken from three experiments (#1-3), under identical vaccination regimens.